发明公开
- 专利标题： USE OF SULCARDINE FOR THE TREATMENT OF ATRIAL FIBRILLATION
- 专利标题（中）： 苏打灵在治疗心房颤动中的应用
-
申请号： EP17182709.0申请日： 2010-11-16
-
公开(公告)号： EP3311810A1公开(公告)日： 2018-04-25
- 发明人: ELLIOT, Gary, T. , WANG, Yiping , BAI, Donglu
- 申请人： Huya Bioscience International LLC , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- 申请人地址： 12531 High Bluff Drive, Suite 138 San Diego, CA 92130 US
- 专利权人： Huya Bioscience International LLC,Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- 当前专利权人： Huya Bioscience International LLC,Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- 当前专利权人地址： 12531 High Bluff Drive, Suite 138 San Diego, CA 92130 US
- 代理机构： Schiweck, Weinzierl & Koch Patentanwälte Partnerschaft mbB
- 优先权： US261925P 20091117
- 主分类号： A61K31/4025
- IPC分类号： A61K31/4025 ; A61K31/402 ; A61K31/40 ; A61K9/22 ; A61K9/20 ; A61K9/08 ; A61P9/00 ; A61P9/06 ; A61K31/18
摘要：
Atrial fibrillation (AF) can be treated or prevented by administering to a subject who suffers from or is at risk of suffering from AF a composition comprised of an amount of an active agent, which is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl) benzene sulfonamide (sulcardine) or a pharmaceutically acceptable salt thereof, such that the Cmax value the active agent in the subject is in the range from about 1 µM to about 20 µM.
公开/授权文献
- EP3311810B1 USE OF SULCARDINE FOR THE TREATMENT OF ATRIAL FIBRILLATION 公开/授权日：2022-07-27
信息查询
IPC分类:
